Home › Funds › STEMPOINT CAPITAL LP › DMRA
STEMPOINT CAPITAL LP position in DMRA
DAMORA THERAPEUTICS INC · Health Care
STEMPOINT CAPITAL LP reported holding 506,067 shares of DMRA (DAMORA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$10.8M, representing 2.16% of its reported portfolio and ranking #18 among its reported holdings. STEMPOINT CAPITAL LP has disclosed DMRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How STEMPOINT CAPITAL LP's DMRA position evolved
STEMPOINT CAPITAL LP first disclosed a stake in DMRA in Q2 2026 at 216,194 shares (US$5.6M). The position peaked in Q3 2026 at 506,067 shares, worth US$10.8M. Across 2 filings, STEMPOINT CAPITAL LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 506,067 shares valued at US$10.8M — an increase of 289,873 shares quarter over quarter.. Notable position changes include a 134% increase in Q3 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 216.19K | $5.62M | New |
| Q3 2026 | 506.07K | $10.77M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DMRA and 13F data
DMRA (DAMORA THERAPEUTICS INC) is a Health Care company. 91 other funds we track also report a position in DMRA — the largest reported positions include Fairmount Funds Management LLC (US$226.6M), Venrock Adviser, LLC (US$93.7M), Avoro Capital Advisors LLC (US$80.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DMRA
- Fairmount Funds Management LLC 8.71M sh · $226.63M · Q2 2026
- Venrock Adviser, LLC 3.60M sh · $93.73M · Q2 2026
- Avoro Capital Advisors LLC 3.78M sh · $80.50M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M sh · $62.42M · Q2 2026
- FCPM III SERVICES B.V. 2.44M sh · $51.94M · Q3 2026
- Commodore Capital LP 1.94M sh · $50.43M · Q2 2026
- Remedium Capital Partners, LLC 2.05M sh · $43.53M · Q3 2026
- BRAIDWELL LP 1.62M sh · $42.15M · Q2 2026
- Bellevue Group AG 1.62M sh · $42.11M · Q2 2026
- a16z Capital Management, L.L.C. 1.24M sh · $32.15M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.22M sh · $31.81M · Q2 2026
- Cormorant Asset Management, LP 1.00M sh · $26.01M · Q2 2026
More on STEMPOINT CAPITAL LP
FAQ
How long has STEMPOINT CAPITAL LP held DMRA?
STEMPOINT CAPITAL LP has disclosed DMRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is STEMPOINT CAPITAL LP's current position in DMRA?
As of Q3 2026, STEMPOINT CAPITAL LP holds 506.07K shares of DMRA (DAMORA THERAPEUTICS INC), valued at $10.77M, representing 2.16% of its reported portfolio and ranking #18.
Has STEMPOINT CAPITAL LP been buying or selling DMRA?
In the latest 13F filing (Q3 2026), STEMPOINT CAPITAL LP increased its position in DMRA. The position peaked in Q3 2026 at 506.07K shares.
Which other funds hold DMRA?
Other major institutional holders of DMRA include Fairmount Funds Management LLC, Venrock Adviser, LLC, Avoro Capital Advisors LLC, among 91 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.